Bladder cancer. A retrospective analysis of the use of vinfluvin in real clinical practice
A. S. Zhabina,
A. I. Novikov,
F. V. Moiseenko,
N. M. Volkov,
E. O. Stepanova,
E. V. Artemeva,
N. H. Abduloeva,
V. M. Moiseenko https://doi.org/10.17709/2410-1893-2021-8-2-3
Abstract
Purpose of the study. There is the generalized analysis of administration of vinflunine in real clinical practice in St.Petersburg Clinical Scientific and Practical Center of Specialized medical Care (oncological).
Materials and methods. This analysis gathered 27 patients with urothelial carcinoma treated using this medicine in St.Petersburg Clinical Scientific and Practical Center of Specialized medical Care (oncological). We assessed efficacy, safety profile of vinflunine in this subset of patients.
Results. Clinical efficacy of vinflunine (complete response + partial response + stable disease) was 51,86 %, one patient demonstrated complete response. Median of response duration accounts for 3,4 months. Adverse events were observed in 28,4 %, most of them were 1-2 grades. 2 patients stopped therapy due to adverse events.
Conclusion. In our analysis vinflunine was more effective than in randomized clinical trial and other studies from real practice in Europe. Thus, confirm expediency to administer of vinflunine for metastatic urothelial carcinoma.
About the Authors
A. S. Zhabina
St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological); N. N.Petrov National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
Albina S. Zhabina – Cand. Sci. (Med.), stuff physician department of chemotherapy department at St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological), 68 A Leningradskaya str., pos. Pesochnyi, Saint-Petersburg 197758; stuff scientist department of innovative methods of therapeutic oncology and rehabilitation N. N. Petrov National Medical Research Center of Oncology (68 Leningradskaya str., pos. Pesochnyi, Saint Petersburg 197758); SPIN: 1724-7764, AuthorID: 803520
Competing Interests:
Аuthors report no conflict of interest.
A. I. Novikov
St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)
Russian Federation
Competing Interests:
Russian Federation
Andrey I. Novikov – Dr. Sci. (Med.), head of the Department of Urology, SPIN: 6189-6347, AuthorID: 396948
68 A Leningradskaya str., pos. Pesochnyi, Saint-Petersburg 197758
Competing Interests:
Аuthors report no conflict of interest.
F. V. Moiseenko
St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological); N. N.Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I. I. Mechnikov
Russian Federation
Competing Interests:
Russian Federation
Fedor V. Moiseenko – Dr. Sci. (Med.), head of the chemotherapy at St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological), 68 A Leningradskaya str., pos. Pesochnyi, Saint-Petersburg 197758; stuff scientist department of innovative methods of therapeutic oncology and rehabilitation N. N. Petrov National Medical Research Center of Oncology (68 Leningradskaya str., pos. Pesochnyi, Saint Petersburg 197758); professor of the department of oncology North-Western State Medical University named after I. I. Mechnikov (41 Kirochnaya str., Saint-Petersburg 191015); SPIN: 7462-2225, AuthorID: 742761, ResearcherID: E-1775-2014
Competing Interests:
Аuthors report no conflict of interest.
N. M. Volkov
St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)
Russian Federation
Competing Interests:
Russian Federation
Nikita M. Volkov – Cand. Sci. (Med.), head of chemotherapy and radiotherapy departments, SPIN: 1605-0256, AuthorID: 883973
68 A Leningradskaya str., pos. Pesochnyi, Saint-Petersburg 197758
Competing Interests:
Аuthors report no conflict of interest.
E. O. Stepanova
St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)
Russian Federation
Competing Interests:
Russian Federation
Ekaterina O. Stepanova – chemotherapy department doctor, SPIN: 3284-5395, AuthorID: 994106
68 A Leningradskaya str., pos. Pesochnyi, Saint-Petersburg 197758
Competing Interests:
Аuthors report no conflict of interest.
E. V. Artemeva
St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)
Russian Federation
Competing Interests:
Russian Federation
Elizaveta V. Artemeva – chemotherapy department doctor
68 A Leningradskaya str., pos. Pesochnyi, Saint-Petersburg 197758
Competing Interests:
Аuthors report no conflict of interest.
N. H. Abduloeva
St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)
Russian Federation
Competing Interests:
Russian Federation
Nuriniso H. Abduloeva – Cand. Sci. (Med.), head of ambulatory department, SPIN: 3882-3299, AuthorID: 62291
68 A Leningradskaya str., pos. Pesochnyi, Saint-Petersburg 197758
Competing Interests:
Аuthors report no conflict of interest.
V. M. Moiseenko
St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)
Russian Federation
Competing Interests:
Russian Federation
Vladimir M. Moiseenko – Dr. Sci. (Med.), professor, director, SPIN: 8184-2980, AuthorID: 602994
68 A Leningradskaya str., pos. Pesochnyi, Saint-Petersburg 197758
Competing Interests:
Аuthors report no conflict of interest.
References
1. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Ed. by A.D.Kaprin, V.V.Starinsky, A.O.Shakhzadova. P.A.Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre. Moscow: 2020, 252 p. (In Russian).
2. Klapheke A, Yap SA, Pan K, Cress RD. Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer. Urol Oncol. 2018 Jun;36(6):308.e19-308.e25. https://doi.org/10.1016/j.urolonc.2018.03.008
3. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005 Jul 20;23(21):4602–4608. https://doi.org/10.1200/JCO.2005.07.757
4. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014 Apr;65(4):778–792. https://doi.org/10.1016/j.eururo.2013.11.046
5. Gladkov OA, Matveev VB, Mitin T, Nosov DA, Popov AM. Practical recommendations for the drug treatment of bladder cancer. Malignant Tumors. 2020;10(3s2-1):542–555. (In Russian). https://doi.org/10.18027/2224-5057-2020-10-3s2-32
6. Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20;27(27):4454–4461. https://doi.org/10.1200/JCO.2008.20.5534
7. Médioni J, Di Palma M, Guillot A, Spaeth D, Théodore C. Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. BMC Cancer. 2016 Mar 14;16:217. https://doi.org/10.1186/s12885-016-2262-9
8. Pistamaltzian N, Tzannis K, Pissanidou V, Peroukidis S, Milaki G, Karavasilis V, et al. Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group. Anticancer Drugs. 2016 Jan;27(1):48–53. https://doi.org/10.1097/CAD.0000000000000297
9. Hussain SA, Ansari J, Huddart R, Power DG, Lyons J, Wylie J, et al. VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. Int J Oncol. 2017 Mar;50(3):768–772. https://doi.org/10.3892/ijo.2017.3847
Review
For citations:
Zhabina A.S., Novikov A.I., Moiseenko F.V., Volkov N.M., Stepanova E.O., Artemeva E.V., Abduloeva N.H., Moiseenko V.M. Bladder cancer. A retrospective analysis of the use of vinfluvin in real clinical practice. Research and Practical Medicine Journal. 2021;8(2):34-42. (In Russ.) https://doi.org/10.17709/2410-1893-2021-8-2-3
Views:
799
Email this article 